[go: up one dir, main page]

UY39764A - NOVEL FORMS OF COMPOUND I AND THEIR USE - Google Patents

NOVEL FORMS OF COMPOUND I AND THEIR USE

Info

Publication number
UY39764A
UY39764A UY0001039764A UY39764A UY39764A UY 39764 A UY39764 A UY 39764A UY 0001039764 A UY0001039764 A UY 0001039764A UY 39764 A UY39764 A UY 39764A UY 39764 A UY39764 A UY 39764A
Authority
UY
Uruguay
Prior art keywords
compound
novel forms
novel
forms
acryloylpiperazin
Prior art date
Application number
UY0001039764A
Other languages
Spanish (es)
Inventor
Wei Long
Lei Zhang
Amin Li
Sujing Li
Chaojie Dang
Xinrui Fan
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of UY39764A publication Critical patent/UY39764A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

<p>La presente invención se relaciona con novedosas formas del Compuesto I y uso de las mismas, en donde, el compuesto es (M)-4-(4-acriloilpiperazin-1-il)-7-(2-amino-3,4,5,6-tetrafluorofenil)-6-cloro-1-(2-isopropil-4-metilpiridin-3-il)-2-oxo-1,2-dihidro-1,8-naftiridin-3-carbonitrilo.</p><p>The present invention relates to novel forms of Compound I and use thereof, wherein the compound is (M)-4-(4-acryloylpiperazin-1-yl)-7-(2-amino-3 ,4,5,6-tetrafluorophenyl)-6-chloro-1-(2-isopropyl-4-methylpyridin-3-yl)-2-oxo-1,2-dihydro-1,8-naphthyridine-3-carbonitrile. </p>

UY0001039764A 2021-05-12 2022-05-11 NOVEL FORMS OF COMPOUND I AND THEIR USE UY39764A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2021093346 2021-05-12

Publications (1)

Publication Number Publication Date
UY39764A true UY39764A (en) 2022-11-30

Family

ID=84027986

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039764A UY39764A (en) 2021-05-12 2022-05-11 NOVEL FORMS OF COMPOUND I AND THEIR USE

Country Status (5)

Country Link
CN (1) CN117295742A (en)
AR (1) AR125835A1 (en)
TW (1) TW202311259A (en)
UY (1) UY39764A (en)
WO (1) WO2022237815A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119136806A (en) 2022-03-08 2024-12-13 锐新医药公司 Methods for treating immune-refractory lung cancer
JP2025521232A (en) 2022-06-10 2025-07-08 レボリューション メディシンズ インコーポレイテッド Macrocyclic RAS inhibitors
EP4687905A1 (en) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
EP4688790A1 (en) 2023-04-07 2026-02-11 Revolution Medicines, Inc. Macrocyclic ras inhibitors
KR20250172857A (en) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Crystalline form of RAS inhibitor
KR20250169290A (en) 2023-04-14 2025-12-02 레볼루션 메디슨즈, 인크. Crystalline form of RAS inhibitor, composition containing same and method of use thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025036470A1 (en) * 2023-08-17 2025-02-20 Jacobio Pharmaceuticals Co., Ltd. Use of compound a for treating a cancer
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7357644B2 (en) * 2018-06-11 2023-10-06 アムジエン・インコーポレーテツド KRAS G12C inhibitors for treating cancer
AU2019336588B2 (en) * 2018-06-12 2022-07-28 Amgen Inc. KRAS G12C inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
CN112225734B (en) * 2019-10-25 2021-12-07 南京瑞捷医药科技有限公司 KRAS G12C inhibitors and uses thereof
WO2021088458A1 (en) * 2019-11-04 2021-05-14 Jacobio Pharmaceuticals Co., Ltd. Kras mutant protein inhibitor
CN115192577B (en) * 2019-12-19 2024-03-29 北京加科思新药研发有限公司 KRAS mutant protein inhibitors

Also Published As

Publication number Publication date
WO2022237815A1 (en) 2022-11-17
CN117295742A (en) 2023-12-26
AR125835A1 (en) 2023-08-16
TW202311259A (en) 2023-03-16

Similar Documents

Publication Publication Date Title
UY39764A (en) NOVEL FORMS OF COMPOUND I AND THEIR USE
ECSP21086530A (en) ITACONIC ACID DERIVATIVES AND USES THEREOF IN THE TREATMENT OF AN INFLAMMATORY DISEASE ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE
MX2022009309A (en) COMPOUNDS AND USES THEREOF.
DOP2018000226A (en) NEW DERIVATIVES OF PIRAZOLOPIRIMIDINA
DOP2019000206A (en) 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES
MX2022005839A (en) COMPOUNDS USEFUL AS INHIBITORS OF THE HELIOS PROTEIN.
UY38793A (en) CHEMICAL COMPOUNDS
MX2021007580A (en) FUSIONED BICYCLIC SOLUBLE GUANYLATE CYCLASE (SGC) STIMULATORS.
UY38070A (en) SUBSTITUTE QUINAZOLINE AND PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS ANTI-CANCER AGENTS
MX2023004920A (en) Bcl6 inhibitors.
MX2022006700A (en) Polyheterocyclic compounds as mettl3 inhibitors.
MX380753B (en) BICYCLIC LACTAMS AND METHODS OF USING THEM.
CO2020001244A2 (en) Quinoline derivatives to treat helminth infections
MA39193B1 (en) Gpr6 modulators based on tetrahydropyridopyrazines
UY37461A (en) 1,2,4 - TRIAZOLONES 2,4,5 TRISUSTITUIDA
AR072016A1 (en) ISOXAZOL DERIVATIVES THAT WORK AS POTENTIALS OF GLUTAMATE RECEIVERS
MX2020013853A (en) INNOVATIVE COMPOUNDS.
MX387590B (en) POLYCYCLIC COMPOUNDS AS BRUTON&#39;S TYROSINE KINASE INHIBITORS.
CR20190566A (en) QUINASA INHIBITORS AND USES OF THEM
CR20210530A (en) 4H-PYRROLO[3,2-C]PYRIDIN-4-ONE COMPOUNDS
CO2020013876A2 (en) New quinoline derivatives
HN2012002039A (en) NON-NUCLEOSIDIC INHIBITORS OF THE REVERSE TRANSCRIPT
EA201892815A1 (en) NEW ANTIBACTERIAL CONNECTIONS
MX2017002913A (en) Crystalline forms of 6- ( (6, 7-dimethoxyquinazolin-4-yl) oxy) -n,2-dimethylbenzofuran-3-carboxamide.
CO2022001257A2 (en) 1,2,4]triazolo[1,5-c]quinazolin-5-amines